Merck suspends TA implant trial

The Phase IIb clinical trial of I-vation TA (Merck & Co), an intravitreal injection incorporating triamcinolone acetonide (TA) for the treatment of diabetic macular oedema (DME), has been suspended.

The Phase IIb clinical trial of I-vation TA (Merck & Co), an intravitreal injection incorporating triamcinolone acetonide (TA) for the treatment of diabetic macular oedema (DME), has been suspended, according to an announcement made by Merck's research and licensing partner, SurModics, Inc.

The trial had been intended to evaluate the safety and efficacy of I-vation TA, an intravitreal implant that delivers TA on a sustained release basis. The minimally invasive implantation procedure is designed to reduce side effects and increase efficacy.

The study, whose design will now be re-evaluated, has been suspended because of the recent publication of study results advocating the superiority of laser treatments over intravitreal TA injections for the treatment of DME. The study did not address I-vation TA directly. Early results from the I-vation TA trial indicate a favourable tolerability profile for the compound.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.